Biohaven Stock Drops 5.3% Amid Market Volatility
Shares of Biohaven Ltd. (NYSE:BHVN) dropped 5.3% due to broader market volatility and mixed analyst ratings, closing at $9.29. Despite HC Wainwright reducing its price target, Goldman Sachs upgraded the stock to a 'strong-buy,' and Citigroup boosted its target price. Investors are closely monitoring the biopharmaceutical company's drug development pipeline amidst these varying expert opinions.
Biohaven (NYSE:BHVN) Trading Down 5.3% - Here's Why
Biohaven (NYSE:BHVN) shares dropped 5.3% on Monday, trading at $9.2850 on significantly lower volume. The company has a "Moderate Buy" consensus rating from analysts with an average price target of $22.64, despite varied individual ratings. Biohaven recently reported an EPS of -$1.21, beating estimates by $0.01, and institutional investors hold a substantial 88.78% of the stock.
BHVN PE Ratio & Valuation, Is BHVN Overvalued
Biohaven Ltd (BHVN) is currently considered undervalued based on its forward PS ratio of 72.15 compared to its five-year average. The fair price for BHVN is estimated to be between $57.76 and $93.89, significantly higher than its current price of $9.80, indicating it is undervalued by 83.03%. While its current P/B ratio is substantially higher than its historical averages, its FCF yield is lower, and its P/S ratio of 72.15 is considered unsustainable given its robust revenue growth compared to competitors.
Biohaven Ltd. (BHVN) stock price, news, quote and history
This article provides a comprehensive overview of Biohaven Ltd. (BHVN), including its current stock price ($9.88, down 0.40%), recent news, and historical performance. The biotech company focuses on developing treatments across immunology, neuroscience, and oncology, with several drug candidates in various clinical trial stages. Key financial metrics, analyst insights, and comparisons to similar companies are also presented.
Why Biohaven (BHVN) Is Up 11.7% After Fully Enrolling Its Phase 2 Obesity Drug Trial
Biohaven Ltd. (BHVN) saw its stock rise by 11.7% after announcing the full enrollment of its Phase 2 trial for taldefgrobep alfa, an obesity treatment. This drug is notable for its potential to reduce fat while increasing lean muscle mass, with topline data expected in late 2026. The advancement of this high-risk asset into a competitive market is a key catalyst for Biohaven, although the company still faces challenges including ongoing losses and funding needs.
Biohaven (BHVN) Short Interest & Short Float | Updated Apr 2026
Biohaven (BHVN) currently has a short interest of 21.90 million shares, representing 16.89% of its public float, as of March 13, 2026. This marks a 4.10% increase from the previous reporting period, indicating a growing bearish sentiment among investors. The short interest ratio is 8.2 days to cover, suggesting that it would take over eight days to cover all short positions given the average trading volume.
Why Biohaven (BHVN) Is Up 11.7% After Fully Enrolling Its Phase 2 Obesity Drug Trial
Biohaven's stock rose 11.7% after the company announced the full enrollment of its Phase 2 trial for taldefgrobep alfa, an obesity treatment. The drug is unique for its ability to promote fat loss and lean muscle gain. Despite this positive development, the company faces challenges with its loss-making status, lack of commercial revenue, and a wide range of fair value estimates from the investment community, highlighting balance sheet risks and potential dilution.
Why Biohaven (BHVN) Is Up 11.7% After Fully Enrolling Its Phase 2 Obesity Drug Trial
Biohaven (BHVN) saw its stock rise by 11.7% after announcing the completion of enrollment for its Phase 2 obesity drug trial of taldefgrobep alfa. This drug is notable for its potential to reduce fat while increasing lean muscle mass, with topline data expected in the second half of 2026. The full enrollment is a positive catalyst for the company, although Biohaven still faces challenges related to its loss-making status and funding needs.
Citigroup Forecasts Strong Price Appreciation for Biohaven (NYSE:BHVN) Stock
Citigroup has increased its price target for Biohaven (NYSE:BHVN) stock from $14 to $17, maintaining a "buy" rating and suggesting a potential upside of 71.20%. Other analysts have mixed ratings, but the consensus remains a "Moderate Buy" with an average target price of $22.64. Despite being unprofitable, Biohaven shows strong institutional ownership and recently surpassed EPS estimates.
Citi Maintains Biohaven(BHVN.US) With Buy Rating, Raises Target Price to $17
Citi has reiterated its Buy rating for Biohaven Pharmaceuticals (BHVN.US) and increased its target price to $17. This indicates a positive outlook from the firm regarding Biohaven's stock performance.
BHVN SEC Filings - Biohaven 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Biohaven (BHVN) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It offers centralized access to the company’s regulatory disclosures, detailed insights into its biopharmaceutical focus, and AI-powered summaries of each filing. Recent filings highlight insider purchases, equity raises, and quarterly financial results.
The Technical Signals Behind (BHVN) That Institutions Follow
This article analyzes Biohaven Ltd. (NASDAQ: BHVN) using AI-generated signals, indicating a weak sentiment across all time horizons supporting a short bias. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, and provides multi-timeframe signal analysis, showing general weakness. The analysis highlights an exceptional 82.7:1 risk-reward short setup, targeting a significant downside.
Biohaven (BHVN) completes enrollment in phase 2 obesity study of taldefgrobep alfa
Biohaven (BHVN) has announced the completion of patient enrollment for its phase 2 clinical trial evaluating taldefgrobep alfa, an anti-myostatin adnectin, for the treatment of obesity. The study aims to assess the drug's efficacy and safety in this patient population. This marks a significant step forward in the development of potential new therapies for obesity.
Biohaven (BHVN) Completes Enrollment in Phase 2 Obesity Study of Taldefgrobep Alfa
Biohaven Ltd. (NYSE:BHVN) has announced the completion of enrollment for its Phase 2 study of taldefgrobep alfa, a treatment for obesity, with topline data expected in the second half of 2026. This news follows a recent price target increase and a maintained "Buy" rating from TD Cowen, driven by positive developments in other pipeline assets. The company is actively advancing its pipeline, particularly its degrader platform, across immunology, neuroscience, and oncology.
Biohaven (NYSE:BHVN) Trading 6.2% Higher - Here's Why
Biohaven's stock rose 6.2% to $9.15 on Thursday, despite sharply lower trading volume. The company faces a high debt-to-equity ratio and negative P/E, though its recent quarterly loss slightly beat estimates. Analyst ratings are mixed with a "Moderate Buy" consensus and an average price target of $22.43.
Can Biohaven (BHVN) Redefine Obesity Treatment By Prioritizing Muscle Preservation Over Pure Weight Loss?
Biohaven has completed enrollment for a Phase 2 trial of taldefgrobep alfa, an obesity treatment designed to reduce fat mass while preserving or increasing lean muscle. This approach differentiates it from many existing treatments and could be a significant long-term growth driver for the company. Despite the potential of this new asset, Biohaven faces financial risks due to its substantial annual losses, lack of revenue, and volatile share price, making execution and funding critical for its future.
Can Biohaven (BHVN) Redefine Obesity Treatment By Prioritizing Muscle Preservation Over Pure Weight Loss?
Biohaven has completed enrollment for its Phase 2 trial of taldefgrobep alfa, an obesity treatment uniquely focused on preserving or increasing lean muscle mass while reducing fat. This approach differentiates it from many existing treatments and could be a significant upside, though the company faces financial risks due to its lack of revenue and substantial losses, making its broad pipeline and funding crucial for future success. Investor opinions on Biohaven's valuation vary widely, underscoring the uncertainty surrounding its complex investment narrative.
Assessing Biohaven (BHVN) Valuation As Losses Persist And Price To Book Hits 25x
Biohaven (BHVN) has garnered investor attention despite a challenging year for its stock, marked by negative returns over recent periods. While the company reports significant annual growth in revenue and net income, it remains unprofitable with a net loss of US$738.8 million and no current revenue. Trading at a high Price to Book ratio of 25.2x, Biohaven's valuation is significantly above industry and peer averages, suggesting investors are paying a premium for its pipeline despite its current loss-making status and weak share performance.
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential
Sarissa Capital Management has initiated a new position in Biohaven Ltd. (BHVN), purchasing 513,184 shares worth $5.79 million in the fourth quarter, despite the stock being down 70% over the past year. This strategic investment by Sarissa, a fund with a strong focus on clinical-stage biotech, suggests potential for a turnaround for Biohaven, which is currently streamlining its late-stage clinical programs and has a strong cash position to fund upcoming crucial clinical readouts. Investors are now looking forward to potential catalysts, including data from a Phase 2 obesity candidate expected in the second half of 2026.
Biohaven Shares Drop 70%, Yet a Fund’s Fresh $6 Million Investment Hints at Possible Recovery
Despite a 70% drop in its share price over the past year, Biohaven Ltd. (NYSE: BHVN) has received a significant vote of confidence from Sarissa Capital Management, which invested $5.79 million in the company during the fourth quarter of 2025. This investment suggests potential for recovery, as Biohaven is strategically focusing on late-stage drug candidates, including a promising obesity drug program with results expected later in 2026, and maintains a resilient financial position.
Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of "Moderate Buy" by Brokerages
Biohaven Ltd. (NYSE:BHVN) has received an average "Moderate Buy" recommendation from seventeen brokerages, with an average 1-year target price of $22.43. Despite a negative PE ratio and forecasted EPS of -8.9, institutional ownership is high at 88.78%, driven by firms like Invesco and HSBC increasing stakes. Recent analyst actions have been mixed, with upgrades from Royal Bank Of Canada and Goldman Sachs, but downgrades from UBS and Weiss Ratings.
DAFNA Capital Management Increases Biohaven Ltd. Investment in 2025 - News and Statistics
DAFNA Capital Management significantly increased its investment in Biohaven Ltd. during Q4 2025, purchasing 720,000 shares valued at $8.92 million. This transaction raised DAFNA's total stake in Biohaven to $10.78 million, making it 2.51% of the firm's U.S. equity portfolio. Biohaven, a clinical-stage biotechnology company, is focusing on late-stage clinical programs despite a 68% stock decline in the preceding year.
Biohaven (NASDAQ: BHVN) director reports gifting 34,684 shares, adds family trust
Biohaven Ltd. director Kishan Mehta reported bona fide gift transfers of 34,684 common shares on March 17, 2026. One transfer of 17,342 shares reduced his directly held stake to 5,320 common shares. The remaining 17,342 shares were transferred to the "Kishen Mehta 21 Family Irrevocable Trust," with Mehta disclaiming beneficial ownership of these securities.
Biohaven shares edge higher after completing enrollment in obesity drug trial
Biohaven Pharmaceutical shares experienced a slight increase after the company announced the completion of patient enrollment for its Phase I clinical trial of BHV-1700, an investigational obesity drug. The trial aims to evaluate the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers. This milestone moves the drug closer to potentially addressing a significant unmet medical need in obesity treatment.
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
Biohaven Ltd. has completed enrollment for its Phase 2 study of taldefgrobep alfa, a myostatin-activin pathway inhibitor, for people with obesity. The drug aims to achieve high-quality weight loss by reducing fat mass while increasing lean muscle mass. Topline data is anticipated in the second half of 2026.
Precision Trading with Biohaven Ltd. (BHVN) Risk Zones
This article provides a precision trading analysis for Biohaven Ltd. (BHVN), noting weak sentiment across all horizons that supports a short bias. It outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, and provides real-time signals, support, and resistance levels across various timeframes. The analysis highlights an exceptional 110.7:1 risk-reward setup targeting a 35.0% gain versus a 0.3% risk.
Biohaven (NYSE: BHVN) outlines R&D pipeline and 2026 shareholder votes
Biohaven Ltd. (NYSE: BHVN) has outlined its strategic research and development pipeline, highlighting progress in extracellular protein degraders for IgA nephropathy and Graves’ disease, the epilepsy treatment opakalim, and the obesity candidate taldefgrobep, as well as oncology programs. Concurrently, the company is preparing for its 2026 annual shareholder meeting on April 28, 2026, where investors will vote on electing three directors, ratifying Ernst & Young LLP as auditor, and an advisory vote on executive compensation. The proxy statement also details Biohaven's robust corporate governance, financial discipline, and executive compensation structure, including its pay-for-performance philosophy and equity ownership guidelines, while also disclosing major institutional shareholders and audit fees for 2025.
Assessing Biohaven (BHVN) Valuation After Pipeline Optimism And Supportive Sector Sentiment
Biohaven (BHVN) is gaining attention due to positive analyst commentary on its epilepsy drug opakalim and supportive sector sentiment. Despite a recent share price decline over the past year, its high price-to-book ratio of 29.7x suggests investors are valuing its pipeline and intellectual property highly. The article advises investors to assess the full risk profile given the company's pre-revenue status and significant net income loss.
TD Cowen Boosts Biohaven (NYSE:BHVN) Price Target to $30.00
TD Cowen has increased its price target for Biohaven (NYSE:BHVN) from $15.00 to $30.00, maintaining a "buy" rating, which suggests a potential upside of 185.77%. Other analysts have also provided varied ratings and target prices, with the consensus being a "Moderate Buy" at $24.93. Institutional investors hold a significant stake in Biohaven, which recently traded at $10.50 after a 2.2% increase.
Assessing Biohaven (BHVN) Valuation After Pipeline Optimism And Supportive Sector Sentiment
Biohaven (BHVN) is gaining attention due to positive analyst commentary on its epilepsy drug opakalim and broader sector optimism. Despite recent share price gains, the company's high price-to-book ratio of 29.7x (compared to peer and industry averages) suggests it may be overvalued, especially given its pre-revenue status and net income loss. Investors are paying a premium for its pipeline, yet there are significant risks to consider.
Biohaven (BHVN) director trust purchase corrected to 28,400 shares
Biohaven Ltd. director John W. Childs filed an amended insider transaction (Form 4/A) to correct a prior filing. The amendment clarifies that 28,400 Common Shares were indirectly purchased by the John W Childs 2013 Revocable Trust at a weighted average price of $30.4266 per share, and no shares were acquired through the 2013 Charitable Remainder Trust in this transaction. The original filing had incorrectly split the purchase between the revocable trust and the charitable remainder trust.
Why Biohaven (BHVN) Is Down 13.5% After Narrower Losses And A New Share Shelf Registration
Biohaven Ltd. reported narrower losses for Q4 and full-year 2025, but the stock still dropped 13.5% due to ongoing concerns about its cash runway and potential dilution. The company also filed a new share shelf registration for an employee stock ownership plan, indicating continued reliance on equity markets despite confidence in its long-term scientific programs. Investors should weigh the improved earnings trend against persistent financing and execution risks.
Biohaven (NYSE:BHVN) Shares Gap Up - Time to Buy?
Biohaven (NYSE:BHVN) shares gapped up before the market open but later traded lower, indicating short-term volatility. The company, a clinical-stage biopharmaceutical firm, holds a "Moderate Buy" consensus rating from Wall Street analysts with an average price target of $23.93. Key financial metrics include a $1.05 billion market cap, negative earnings, and significant institutional ownership.
Assessing Biohaven (BHVN) Valuation After Recent Share Price Volatility
Biohaven (BHVN) has experienced significant share price volatility, with a recent 9.7% decline, contributing to a 10% drop over the past week and month, despite a 66% decline over the last year. The company's price-to-book ratio of 27.2x is considerably higher than its industry and sector averages, suggesting investors are valuing its pipeline heavily due to current losses and no revenue. This premium valuation could be at risk if clinical trials fail or if further capital raises are needed.
Biohaven Ltd. (BHVN) SVP awarded 175,000 stock options with 4-year vesting
Biohaven Ltd.'s SVP of Clinical Operations, Kimberly Gentile, was granted 175,000 stock options on February 27, 2026. These options will vest in four equal annual installments through February 27, 2029, contingent on her continued employment. The transaction was reported in a Form 4 SEC filing, indicating an acquisition of derivative securities.
Biohaven (BHVN) CEO Vlad Coric granted 550,000 stock options
Biohaven Ltd. CEO Vlad Coric was granted 550,000 stock options on February 27, 2026, as reported in a recent Form 4 SEC filing. These options have a stated price of $0.00 per share and will vest in four equal annual installments between 2026 and 2029, contingent on his continued service at Biohaven. This transaction increases his directly held option position to 550,000 derivative securities.
Key facts: Biohaven posts $738.8M loss; opakalim shows promise in study; analysts give 'buy' rating
Biohaven Ltd. (BHVN) reported a net loss of $738.8 million in 2025, an improvement over the previous year, with no product revenue. Despite the loss, the company's Kv7 channel activator, opakalim, demonstrated strong results in a focal epilepsy study, and analysts maintain a 'buy' rating for BHVN with a target price indicating a potential 26.2% upside.
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 77% Potential Upside with Strong Buy Ratings
Biohaven Ltd. (BHVN) is a biotechnology company focused on neurological and oncological therapies, attracting investor attention with a potential upside of 77.29% based on analyst ratings. Despite its current unprofitability due to significant R&D investments, exemplified by a negative P/E ratio and EPS, the company holds a $1.57 billion market capitalization and has multiple late-stage clinical trials underway. Strong analyst confidence, indicated by 13 buy ratings against 5 hold ratings, along with strategic partnerships, suggests a promising long-term growth trajectory in its high-risk, high-reward sector.
Piper Sandler reiterates Biohaven stock rating on 2026 catalysts
Piper Sandler reiterated an Overweight rating and $30.00 price target on Biohaven Pharma, anticipating multiple clinical trial readouts in 2026, including data for azetukalner in focal epilepsy this month and upcoming pivotal trials for BHV-1400 IgAN and BHV-1300 Graves’ disease. The firm highlighted Biohaven's narrowed pipeline focus, catalyst flow, and potential for non-dilutive capital through partnering non-priority assets. This re-rating comes amidst other positive analyst assessments and promising early clinical results for the company’s protein degrader platforms.
Biohaven (BHVN) CFO awarded 175,000 stock options in Form 4 filing
Biohaven Ltd.'s Chief Financial Officer, Matthew Buten, was granted 175,000 stock options according to a recent Form 4 filing. These compensation-related options will vest in four equal installments on February 27 of 2026, 2027, 2028, and 2029, provided he remains employed by the company. This grant increases his directly owned derivative holdings in Biohaven to 175,000 options.
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
Biohaven Ltd. has reported its financial results for the fourth quarter and full year ended December 31, 2025, alongside significant advancements in its clinical pipeline. The company is prioritizing three late-stage clinical programs: extracellular protein degradation for immunological diseases (Graves' Disease and IgA Nephropathy), Kv7 ion channel modulation for epilepsy, and myostatin-activin pathway targeting for obesity. Biohaven also highlighted its disciplined balance sheet management, capital preservation efforts, and upcoming pivotal study initiations and topline data expectations for 2026.
How US$600 Million Non-Dilutive Funding and R&D Cuts Will Impact Biohaven (BHVN) Investors
Biohaven recently secured US$600 million in non-dilutive funding from Oberland Capital and implemented a 60% reduction in R&D spending. This move aims to extend its cash runway and support clinical programs in neurology, immunology, and oncology, while limiting shareholder dilution. The funding reshapes Biohaven's investment narrative, reducing immediate financing pressure but also raising questions about the pace and breadth of future clinical trials.
Assessing Biohaven (BHVN) Valuation After A Sharp One Year Decline And Recent Three Month Rebound
Biohaven (BHVN) has experienced a mixed stock performance recently, with a 25.1% gain in the last three months contrasting a 67.4% decline over the past year. The company is currently loss-making with negative shareholder equity, making traditional valuation methods like P/B ratio and DCF models difficult to apply. Investors are thus focusing on its pipeline and forecast revenue growth of 61.3% annually, while also considering significant risks associated with its financial position.
Assessing Biohaven (BHVN) Valuation After A Sharp One Year Decline And Recent Three Month Rebound
Biohaven (BHVN) has seen a recent rebound with a 25.1% gain over the past three months, despite a 67.4% decline over the past year. The company is currently loss-making with negative shareholder equity, making traditional valuation metrics like Price-to-Book difficult to interpret and a DCF model unreliable due to insufficient future cash flow data. Investors are advised to focus on the company's pipeline and forecast revenue growth, while also considering the risks associated with its net loss and lack of current revenue.
Piper Sandler reiterates Biohaven stock rating on epilepsy trial
Piper Sandler reiterated an Overweight rating and a $30.00 price target on Biohaven Pharma (NYSE:BHVN) stock due to updates in the company's clinical programs, specifically a dosing change in the pivotal RISE 2 trial for focal epilepsy which they believe increases the probability of success. The firm also assigned value to Biohaven's degrader platform for Graves’ Disease and IgAN, considering these significant value drivers. Goldman Sachs, RBC Capital, and Baird have also issued positive ratings, while Stifel maintained a cautious stance on a different drug comparison.
Biohaven (BHVN) Projected to Post Earnings on Monday
Biohaven (BHVN) is anticipated to release its Q4 2025 earnings before market open on Monday, March 2nd, with analysts forecasting a loss of ($1.22) per share. Despite a "Moderate Buy" consensus rating, the stock trades significantly below its consensus price target of $25.40, following recent price target reductions by several analysts. Institutional investors hold a substantial 88.8% of the company's stock, with notable repositioning by various hedge funds and asset managers.
Trading the Move, Not the Narrative: (BHVN) Edition
This article analyzes Biohaven Ltd. (NASDAQ: BHVN), highlighting weak sentiment across all time horizons, supporting a short bias. It details an exceptional 112.5:1 risk-reward short setup targeting 34.5% downside against a minimal 0.3% risk. The piece also outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis.
Pfizer’s Biohaven deal pays dividends with new drug approval
The FDA has approved Pfizer's new migraine nasal spray, Zavzpret, which was a key asset in its roughly $12 billion acquisition of Biohaven Pharmaceuticals last year. This approval bolsters Pfizer's migraine portfolio, including Nurtec ODT, and is expected to contribute to combined peak yearly sales of over $6 billion for both drugs, helping to offset anticipated declines in COVID-19 treatment sales and patent expirations. Zavzpret offers rapid pain relief and an alternative for patients unable to take oral medications, though altered taste and nasal discomfort were common side effects.
Raymond James Begins Coverage of Biohaven with Strong Buy Rating and Sets Price Target at $75
Raymond James has initiated coverage on Biohaven (BHVN) with a "Strong Buy" rating and a price target of $75. This positive outlook is supported by recent analyst upgrades from Goldman Sachs and RBC Capital, who also provided optimistic ratings and price targets. Biohaven is highlighted for its diverse pipeline in immunology, neuroscience, and oncology, with promising clinical data for treatments in IgA nephropathy, Graves' disease, and epilepsy, and upcoming pivotal trial results expected in 2026.
Assessing Biohaven (BHVN) Valuation As Analyst Optimism And Earnings Estimates Improve
Biohaven (BHVN) is gaining attention due to improved analyst sentiment and a favorable Zacks Rank, despite past share price volatility. The article highlights that its negative price-to-book ratio makes traditional valuation difficult for the loss-making biotech, suggesting investors focus instead on pipeline progress and future revenue expectations. The current analyst target is above the stock's present price, raising questions about whether it is undervalued or if its growth potential is already priced in.
